Department of Pediatric Gastroenterology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.
Inflamm Bowel Dis. 2012 May;18(5):985-1002. doi: 10.1002/ibd.21871. Epub 2011 Sep 20.
Infliximab, adalimumab, and certolizumab are monoclonal antibodies against tumor necrosis factor-α (TNFα), a proinflammatory cytokine with an increased expression in the inflamed tissues of inflammatory bowel disease (IBD) patients. Currently, infliximab is the only anti-TNF drug that has been approved for use in refractory pediatric Crohn's disease (CD). Nevertheless, adalimumab and certolizumab have been used off-label to treat refractory pediatric IBD. Over the past 10 years, anti-TNF treatment has been of great benefit to many pediatric IBD patients, but their use is not without risks (infections, autoimmune diseases, malignancies). Despite the growing experience with these drugs in children with IBD, optimal treatment strategies still need to be determined. The purpose of this review is to summarize the current knowledge on the use of anti-TNF drugs in pediatric IBD and to discuss the yet-unsolved issues.
英夫利昔单抗、阿达木单抗和 Certolizumab 是针对肿瘤坏死因子-α（TNFα）的单克隆抗体，TNFα 是一种促炎细胞因子，在炎症性肠病（IBD）患者的炎症组织中表达增加。目前，英夫利昔单抗是唯一被批准用于治疗难治性儿童克罗恩病（CD）的抗 TNF 药物。然而，阿达木单抗和 Certolizumab 已被用于治疗难治性儿童 IBD 的标签外。在过去的 10 年中，抗 TNF 治疗对许多儿童 IBD 患者非常有益，但它们的使用并非没有风险（感染、自身免疫性疾病、恶性肿瘤）。尽管儿童 IBD 患者使用这些药物的经验不断增加，但仍需要确定最佳治疗策略。本综述的目的是总结抗 TNF 药物在儿科 IBD 中的应用现状，并讨论尚未解决的问题。
